Wormentel 150 vs 222 mg: Uses and Safety
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Sept 16 2026
Wormentel 150 and Wormentel 222 are tablet strengths marketed as containing fenbendazole, an antiparasitic medicine primarily used in veterinary medicine to treat certain worm infections. The main difference in Wormentel 150 vs 222 mg is the amount of fenbendazole in each tablet: 150 mg versus 222 mg, not a different active ingredient. Importantly, a higher-strength tablet should not be interpreted as a stronger or more appropriate treatment for a person. Fenbendazole has established veterinary uses, but it is not FDA-approved for treating cancer or other diseases in humans, and reliable human dosing and safety information is limited. Interest in fenbendazole has increased online, particularly around unproven cancer claims, making the distinction between veterinary evidence, laboratory research, case reports, and proven human treatment especially important. This guide compares the two Wormentel strengths, explains fenbendazole's established uses, and reviews the most important safety concerns.
What Is the Difference Between Wormentel 150 and 222 mg?
Wormentel 150 and Wormentel 222 are marketed as different strengths of fenbendazole tablets. Available product information identifies Wormentel 150 as containing 150 mg of fenbendazole per tablet and Wormentel 222 as containing 222 mg.
That means one 222 mg tablet contains 72 mg more fenbendazole than one 150 mg tablet. In percentage terms, 222 mg is about 48% more fenbendazole than 150 mg.
That numerical comparison does not establish that 222 mg is more effective, safer, or appropriate for a particular person or animal. Antiparasitic dosing depends on factors such as the species being treated, body weight, parasite involved, formulation, approved product directions, and veterinary guidance.
Wormentel 150 vs 222 mg comparison
Feature | Wormentel 150 mg | Wormentel 222 mg |
Listed active ingredient | Fenbendazole | Fenbendazole |
Strength per tablet | 150 mg | 222 mg |
Drug class | Anthelmintic/antiparasitic | Anthelmintic/antiparasitic |
Difference in active ingredient | None identified | None identified |
Main difference | Lower amount per tablet | Higher amount per tablet |
Established role of fenbendazole | Veterinary antiparasitic treatment | Veterinary antiparasitic treatment |
Approved human cancer treatment? | No established approval | No established approval |
Human dose established from these strengths? | No | No |
The 150 mg and 222 mg numbers describe how much fenbendazole is in a tablet. They do not establish a medically appropriate human dose, and the 222 mg strength should not be assumed to provide greater benefit simply because it contains more drug.
What Is Fenbendazole Actually Used For?
Fenbendazole is a benzimidazole anthelmintic—a medicine designed to control parasitic worms. Its established regulatory and clinical role is primarily in veterinary medicine rather than routine human treatment.
Veterinary parasite treatment
Fenbendazole is used in animals against susceptible gastrointestinal and other parasites. Depending on the approved veterinary product and animal species, these can include certain roundworms, hookworms, whipworms, lungworms, and other parasites.
The exact approved uses vary by species and formulation. In January 2026, for example, the FDA approval information for veterinary fenbendazole described an approved fenbendazole oral suspension for controlling specified lungworms, stomach worms, and intestinal worms in cattle and stomach worms in goats.
This is an important distinction because veterinary approval does not establish that a medicine is safe or effective for humans.
Is fenbendazole approved for human treatment?
Fenbendazole is not FDA-approved for human use. The American Cancer Society states that fenbendazole is intended for animals and has not been approved by the FDA for humans for any purpose.
Some online listings may describe fenbendazole products as human medicines or even appear in drug-label databases. That alone does not establish regulatory approval. For example, a DailyMed listing for a 222 mg fenbendazole capsule explicitly states that the product has not been found by the FDA to be safe and effective and that its labelling has not been FDA-approved.
The FDA explanation of how to identify an approved human drug notes that FDA-approved human drugs can be checked through official resources such as Drugs@FDA.
Is Wormentel 150 or 222 mg Used for Cancer?
Neither Wormentel 150 mg nor Wormentel 222 mg is an established, FDA-approved cancer treatment.
Fenbendazole has attracted research and online attention for possible anticancer effects, but laboratory findings and individual case reports do not establish that it treats cancer safely or effectively in humans.
Why is fenbendazole discussed in cancer communities?
Researchers have studied fenbendazole in laboratory and preclinical models because it can affect cellular processes that may also be relevant to cancer biology. Preclinical research can help scientists decide whether a compound deserves further study, but it cannot determine a safe or effective cancer dose for people.
Some published case reports and case series describe people with cancer who self-administered fenbendazole. A 2025 case series, for example, reported favourable outcomes in three patients, but the patients also received other cancer treatments, and a small uncontrolled case series cannot demonstrate that fenbendazole caused the outcomes.
This is why evidence hierarchy matters. Randomised controlled human trials can answer questions about treatment benefits and risks much more reliably than testimonials, laboratory experiments, or a handful of individual cases.
Does the 222 mg dose have proven anticancer benefits?
No reliable evidence establishes 222 mg of fenbendazole as an effective cancer dose in humans. The appearance of 222 mg in online protocols or individual case reports should not be interpreted as clinical validation.
Published cases sometimes describe people taking 222 mg, but a reported dose is not the same as a scientifically established dose. Without controlled trials establishing pharmacology, effectiveness, treatment duration, interactions, and safety, these reports cannot provide a standard human cancer regimen.
The American Cancer Society review of fenbendazole explains that there is currently no solid evidence establishing fenbendazole as a safe and effective cancer treatment in people.
People receiving cancer treatment should discuss supplements, veterinary medicines, and other self-directed therapies with their oncology team because these products may cause harm, complicate treatment, or make side effects more difficult to interpret.
Is 222 mg Stronger or Safer Than 150 mg?
Wormentel 222 mg contains more fenbendazole per tablet than Wormentel 150 mg, but that does not make it inherently better or safer. Safety cannot be determined from tablet strength alone.
For an approved medicine, clinicians normally choose doses using evidence from pharmacology studies and clinical trials. Relevant factors may include body weight, medical condition, kidney or liver function, other medicines, treatment duration, and the drug's approved dosing instructions.
Those principles are particularly important here because established human dosing standards for fenbendazole have not been defined through the type of regulatory evidence available for approved human medicines.
Taking a lower-strength tablet also does not make unsupervised human use safe. Repeated exposure, total dose, duration of treatment, underlying liver health, other medicines, and individual susceptibility can all influence risk.
Dos and don'ts when comparing Wormentel strengths
Do | Don't |
Check the active ingredient and strength on the actual package | Do not assume 222 mg is better because the number is higher |
Recognise that fenbendazole's established use is primarily veterinary | Do not treat veterinary use as proof of human safety |
Discuss any intended human use with an appropriate healthcare professional | Do not create a human dose from animal dosing instructions |
Tell your doctor about fenbendazole if you have already taken it | Do not hide non-prescription or veterinary products from your medical team |
Seek medical assessment for symptoms suggesting liver injury or allergy | Do not use online testimonials as substitutes for clinical evidence |
Follow evidence-based cancer or parasite treatment recommendations | Do not replace proven treatment with fenbendazole based on online claims |
What Are the Safety Concerns With Fenbendazole in Humans?
The central safety problem is that fenbendazole does not have the established human safety profile, approved indications, and standard dosing instructions expected of an approved human medicine. That uncertainty becomes particularly important when people take veterinary products repeatedly or combine them with prescription treatments.
Liver injury
Drug-induced liver injury is one of the most important reported concerns associated with human self-administration of fenbendazole.
A published case described a 67-year-old woman who developed severe liver injury after self-administering veterinary fenbendazole. Liver biopsy findings supported drug-induced liver injury, and her liver tests eventually normalised after fenbendazole was stopped.
Another published cancer case described liver dysfunction associated with self-administered fenbendazole, with improvement after discontinuation. More recently, a 2026 report described probable fenbendazole-associated drug-induced liver injury after 222 mg daily was taken for several weeks.
These are case reports, so they cannot determine how frequently liver injury occurs. They do show, however, that assuming fenbendazole is harmless because it is a veterinary dewormer is not justified.
Unknown interactions and long-term risks
Human information about interactions between fenbendazole and prescription medicines is limited. This is particularly relevant for people receiving chemotherapy, immunotherapy, targeted cancer drugs, anticoagulants, or other treatments where unexpected toxicity could have serious consequences.
Without adequate controlled human studies, it is also difficult to define the risks of repeated or long-term exposure.
Product quality and formulation
Veterinary products are developed and labelled for specific animal uses. Their formulation, approved dosing directions, manufacturing requirements, and intended populations should not automatically be extrapolated to humans.
Likewise, a product being available for purchase online does not prove that it has been evaluated and approved as a human medicine. Regulatory status should be checked independently rather than inferred from packaging or retailer descriptions.
How Should You Choose Between Wormentel 150 and 222 mg?
For human self-treatment, there is no evidence-based basis for choosing Wormentel 150 mg over 222 mg—or 222 mg over 150 mg—because neither strength provides an established human fenbendazole regimen simply by virtue of the tablet strength.
If the goal is treatment of a suspected parasitic infection in a person, proper diagnosis matters. Different parasites require different medicines, and several antiparasitic medicines are specifically approved for human use. A clinician can select treatment based on the parasite, symptoms, exposure history, laboratory findings when necessary, age, pregnancy status, and other health considerations.
If the reason for considering fenbendazole is cancer, neither tablet strength should be substituted for established oncology treatment. The absence of proven benefit is especially important when delaying effective treatment could allow cancer to progress.
For veterinary treatment, the correct product and dose should be selected according to the animal species, weight, parasite, product label, and veterinary advice rather than by comparing tablet strengths alone.
When Should You Seek Medical Care?
Anyone who has taken fenbendazole and develops symptoms suggesting liver injury or another serious reaction should seek medical assessment. Tell the healthcare professional exactly what product was taken, the strength, approximate amount, frequency, duration, and any other medicines or supplements being used.
Seek prompt medical care for symptoms such as:
Yellowing of the skin or eyes
Dark urine or unusually pale stools
Persistent nausea or vomiting
Significant abdominal pain
Severe or unexplained fatigue
Loss of appetite accompanied by other concerning symptoms
Widespread rash or facial swelling
Difficulty breathing
Confusion or marked deterioration in general health
Cancer patients should also tell their oncology team about fenbendazole use even if they currently feel well. This information can be important when doctors interpret liver tests, treatment side effects, or changes in the underlying disease.
Conclusion
The key difference in Wormentel 150 vs 222 mg is straightforward: both are marketed as fenbendazole tablets, while the 222 mg tablet contains more active ingredient per tablet. That difference does not establish a preferred or safe human dose. Fenbendazole has recognised veterinary antiparasitic uses, but evidence is insufficient to establish it as a safe and effective human cancer treatment, and published cases have linked self-administration with serious liver injury.
If you are considering fenbendazole for a human parasitic infection, cancer, or another condition, speak with a qualified healthcare professional about evidence-based options rather than selecting a Wormentel strength yourself.
Frequently Asked Questions
1. What is the difference between Wormentel 150 mg and 222 mg?
Both products are marketed as containing fenbendazole, but the amount per tablet differs. Wormentel 150 contains 150 mg, while Wormentel 222 contains 222 mg. The higher number does not establish greater effectiveness or an appropriate human dose.
2. Is Wormentel 222 mg stronger than 150 mg?
Wormentel 222 contains about 48% more fenbendazole per tablet than the 150 mg strength. However, “stronger” does not mean safer or more effective for a particular condition. Appropriate dosing depends on an established indication and evidence-based treatment guidance.
3. Is Wormentel fenbendazole approved for humans?
Fenbendazole is not FDA-approved for human use. Its established role is primarily as a veterinary antiparasitic medicine. Online availability or a product listing should not be confused with regulatory evidence showing that a formulation is safe and effective for people.
4. Can Wormentel 222 mg treat cancer?
There is no established evidence that Wormentel 222 mg treats cancer in humans. Laboratory research and case reports have generated interest, but they cannot establish effectiveness or a safe cancer dose. Fenbendazole should not replace evidence-based oncology treatment.
5. Can fenbendazole damage the liver?
Serious drug-induced liver injury has been reported in people who self-administered fenbendazole. Case reports cannot determine how common this complication is, but they establish a meaningful safety concern. Yellow skin or eyes, dark urine, or significant illness requires medical assessment.
6. Which is safer, Wormentel 150 or 222 mg?
There is not enough human clinical evidence to declare one Wormentel strength safer for human use. A smaller amount per tablet does not automatically make self-treatment safe. Anyone considering fenbendazole for a medical condition should discuss approved, evidence-based alternatives with a healthcare professional.
Comments